News/November 22, 2026

Research indicates semaglutide reduces body weight by 15% in individuals with blood sugar issues — Evidence Review

Published by researchers at University of Alberta

Researched byConsensus— the AI search engine for science

Table of Contents

Some people taking GLP-1 medications like semaglutide (Ozempic/Wegovy) experience significant weight loss, while others see modest or stalled results, possibly due to differences in energy metabolism and metabolic adaptation, according to new research from the University of Alberta. Most related studies agree that semaglutide consistently leads to clinically significant weight loss, but individual responses vary, and the reasons for this variability remain under investigation.

  • The variability in weight loss outcomes with semaglutide is supported by large randomized trials and meta-analyses, which show that while average weight loss is substantial, some individuals experience less pronounced benefits, potentially due to differences in metabolism, genetics, and comorbidities 1 6 7 8.
  • Multiple studies indicate that metabolic adaptation—where the body reduces its energy expenditure as weight is lost—may contribute to weight plateaus or reduced effectiveness over time; however, the direct impact of GLP-1 medications on energy metabolism is not yet clearly established 5.
  • Sex, diabetes status, and genetic factors such as ARRB1 variants have all been identified as influencing individual responses to semaglutide and other GLP-1 receptor agonists, highlighting the need for personalized approaches to obesity management 6 7 8.

Study Overview and Key Findings

Understanding why some individuals lose more weight on semaglutide than others is increasingly important as these medications become common in obesity and diabetes care. The study from the University of Alberta explores the hypothesis that metabolic adaptation—where the body reduces its calorie expenditure during weight loss—may be a key factor underlying this variability. Unlike many clinical trials that focus solely on weight change, this research uses advanced technology to measure participants’ energy use over time, aiming for a more personalized understanding of how semaglutide affects weight, metabolism, and body composition.

Property Value
Organization University of Alberta
Authors Giovanna Guimaraes Lopes Bergamasco, Andrea M. Haqq, Carla Prado, Rachel J. Skow
Population Individuals with blood sugar regulation issues
Outcome Changes in body weight, composition, and energy utilization
Results Semaglutide reduces body weight by an average of 15 percent

To situate the new findings within the broader scientific landscape, we searched the Consensus database, which contains over 200 million research papers. The following queries were used to identify the most relevant and recent literature:

  1. semaglutide weight loss variability
  2. Ozempic effectiveness individual differences
  3. semaglutide long-term weight loss outcomes

Summary Table of Key Topics and Findings

Topic Key Findings
Why do some people lose more weight on semaglutide than others? - Individual responses vary due to genetics (e.g., ARRB1/GLP1R variants), sex, baseline metabolic status, and comorbidities 6 7 8.
- Females tend to lose more weight than males on GLP-1RAs, and diabetes status predicts a weaker weight loss response 7 8.
What are the long-term effects and sustainability of semaglutide? - Semaglutide produces substantial, sustained weight loss over 1–4 years in both clinical trials and real-world settings 1 2 3 4 5 9 13.
- Higher doses (e.g., 7.2 mg) may yield greater weight loss, but most individuals maintain significant reductions at standard doses 4 13.
How do metabolic adaptation and energy use impact outcomes? - Metabolic adaptation (a drop in calorie expenditure) may limit weight loss; studies on whether semaglutide affects this adaptation are inconclusive or ongoing 5.
- Loss of fat-free mass (muscle) alongside fat may reduce resting energy expenditure, contributing to weight loss plateaus 5.
What is the effect of semaglutide in different patient populations? - Individuals with type 2 diabetes generally experience less weight loss than those without diabetes, possibly due to medication effects, chronicity of obesity, and other metabolic factors 8 9 11.
- Genetic, sex, and pathophysiological differences further modulate response 6 7 10.

Why do some people lose more weight on semaglutide than others?

The new study’s focus on individual variability aligns with a growing body of evidence that genetic, biological, and demographic factors influence weight loss outcomes with semaglutide. Recent meta-analyses and genetic studies have identified specific genetic variants, such as those in ARRB1 and GLP1R, that affect response to GLP-1 receptor agonists. Sex differences have also been documented, with females generally achieving greater weight loss than males. Additionally, diabetes status and baseline metabolic health play a role in determining the degree of benefit.

  • Variants in ARRB1 and GLP1R genes are associated with differences in glycemic and weight responses to GLP-1 therapies, suggesting a role for pharmacogenomics in personalizing treatment 6.
  • Meta-analyses confirm that females lose more weight than males on GLP-1RAs, and this difference increases with greater weight loss 7.
  • Individuals with type 2 diabetes typically experience less weight loss with semaglutide than those without diabetes, likely due to physiological and behavioral factors 8.
  • Continuous clinical variables (BMI, insulin resistance, etc.) may predict treatment response more accurately than simple subgroup stratification 10.

What are the long-term effects and sustainability of semaglutide?

Sustained weight loss is a central goal in obesity management. Multiple large-scale RCTs and real-world studies demonstrate that semaglutide provides clinically significant, long-term weight reduction for most users, with effects lasting up to four years. While higher doses may produce somewhat greater reductions, standard therapeutic doses are effective for the majority of patients.

  • Semaglutide 2.4 mg leads to average weight losses of 10–15% over 1–2 years, and 10% or more at four years, with improvements in cardiometabolic risk factors 1 2 3 5 13.
  • Oral and injectable semaglutide formulations both produce sustained weight loss across diverse populations 5 13.
  • Higher doses (e.g., 7.2 mg) produced even greater weight loss in clinical trials, with acceptable safety profiles 4.
  • Real-world data confirm efficacy across various baseline characteristics, supporting generalizability to clinical practice 9.

How do metabolic adaptation and energy use impact outcomes?

Metabolic adaptation—the reduction in resting energy expenditure as people lose weight—can limit further weight loss and contribute to plateaus, a phenomenon observed across weight loss interventions. The new study highlights the need for more research on whether semaglutide modifies this adaptation, as this could inform strategies to maximize and sustain weight reduction.

  • Semaglutide’s direct effects on resting energy expenditure remain unclear; existing studies report neutral or inconclusive findings, highlighting a gap in knowledge 5.
  • Both fat and fat-free mass loss decrease total energy expenditure, potentially leading to metabolic slowing and weight plateaus 5.
  • Resistance exercise and higher protein diets may help preserve muscle mass and mitigate reductions in energy expenditure during weight loss 5.
  • Understanding the interaction between semaglutide, energy metabolism, and body composition is key to identifying individuals at risk of non-response or weight regain 5.

What is the effect of semaglutide in different patient populations?

Weight loss outcomes with semaglutide are not uniform across all patient groups. People with type 2 diabetes, for example, tend to experience less weight loss than those without diabetes. This may reflect the influence of background medications, the chronicity of obesity, and altered metabolic states. Additionally, recent studies suggest that pathophysiological subtypes of diabetes and continuous metabolic variables may help predict who will benefit most.

  • Individuals with type 2 diabetes lose less weight on semaglutide than those without diabetes, with average reductions of 6–10% versus 10–15% 8 9 11.
  • Differences in underlying metabolism, duration of obesity, and medication use contribute to this variability 8.
  • Stratifying patients by continuous variables (BMI, insulin resistance) rather than broad subgroups may enhance prediction of response 10.
  • Genetic and sex differences further influence outcomes, underscoring the need for individualized approaches 6 7.

Future Research Questions

Despite considerable progress, important gaps remain in understanding the mechanisms underlying individual variability in semaglutide response, the role of metabolic adaptation, and the optimization of treatment for diverse patient populations. Addressing these gaps will enable more personalized and effective obesity therapies.

Research Question Relevance
How does semaglutide affect resting energy expenditure and metabolic adaptation during weight loss? Direct measurement of energy expenditure changes with semaglutide is needed to determine if it helps overcome metabolic adaptation, which could inform strategies to prevent weight plateaus 5.
What genetic or biological factors predict non-response to semaglutide weight loss therapy? Identifying predictors such as GLP1R/ARRB1 variants or metabolic markers could enable personalized treatment and early identification of likely non-responders 6 7 10.
How can lifestyle interventions be optimized to support semaglutide-induced weight loss and preserve muscle mass? Approaches such as resistance training and dietary protein may help prevent loss of fat-free mass and limit metabolic slowing, optimizing long-term outcomes 5.
Does semaglutide demonstrate different efficacy and safety profiles in diverse demographic or clinical populations? Sex, age, ethnicity, and diabetes status all appear to influence outcomes; further research can clarify how to tailor treatment to maximize benefit and minimize risk 7 8 9 11.
What are the long-term effects of semaglutide on weight maintenance, metabolic health, and quality of life? While long-term RCTs show sustained weight loss, questions remain about maintenance after discontinuation, durability of metabolic benefits, and effects on physical and mental well-being 2 3 13.

Sources